April 30, 2017 6:59 AM ET


Company Overview of Celyad SA

Company Overview

Celyad SA, a biopharmaceutical company, focuses on engineered cell therapy treatments. It operates in two segments, Cardiology and Immuno-oncology. The company’s lead product candidate in cardiovascular disease is C-Cure, an autologous cell therapy for the treatment of patients with ischemic heart failure. Its lead product candidate in oncology disease is CAR-T NKR-2, an autologous chimeric antigen receptor (CAR) for the treatment of cancer. In addition, the company’s preclinical stage product candidates include NKp30, an activated receptor of NK cells; B7H6 therapies, which kills cancer cells; and CAR T-cell, an allogeneic T-cell platform. Further, it offers C-CATHez, a cell injection cathe...

Axis Business Park

Rue Edouard Belin 12

Mont-Saint-Guibert,  1435


Founded in 2004

84.6 Employees


32 1 039 41 00


32 1 039 41 41

Key Executives for Celyad SA

Chief Executive Officer and Executive Director
Age: 58
Total Annual Compensation: €562.0K
Compensation as of Fiscal Year 2016.

Celyad SA Key Developments

Celyad Initiates Second Dose Escalation in THINK Trial in First US Patient

Celyad announced the dosing of the first patient of the second dose in the solid tumor arm of its THINK trial (THerapeutic Immunotherapy with NKR-2). This first ovarian cancer patient has been dosed at Roswell Park Cancer Institute (Buffalo, New York). At the first solid tumor dose-level, one pancreatic and two colorectal cancer patients were successfully dosed. None of these patients experienced dose limiting adverse events. THINK is a multinational open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 T-cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). These cancer indications were selected based on strong preclinical evidence and NKG2D ligand expression. The THINK trial is being conducted in the US and in Europe. It contains a dose escalation and an extension stage. The dose escalation is conducted in parallel in the solid and liquid cancer groups, while the extension phase will evaluate in parallel each tumor independently. The dose escalation design includes three dose levels adjusted to body weight: up to 3x108, 1x109 and 3x109 NKR-2 T-cells. At each dose, the patients receive three successive administrations, two weeks apart, of NKR-2 T-cells at the specified dose.

Celyad SA Presents at 10th Kempen & Co Life Sciences Conference, Apr-19-2017

Celyad SA Presents at 10th Kempen & Co Life Sciences Conference, Apr-19-2017 . Venue: Kempen & Co Offices, Beethovenstraat 300, Amsterdam, Netherlands.

Celyad SA Announces Consolidated Earnings Results for the Year Ended December 31, 2016

Celyad SA announced consolidated earnings results for the year ended December 31, 2016. For the period, the company’s revenue was EUR 8,523,000 as compared to EUR 3,000 for the same period last year. Loss before taxes was EUR 23,612,000 as compared to EUR 29,114,000 for the same period last year. Loss for the year was EUR 23,606,000 as compared to EUR 29,114,000 for the same period last year. Basic and diluted loss per share was EUR 2.53 as compared to EUR 3.43 for the same period last year. Net cash used in operations was EUR 24,692,000 as compared to EUR 27,303,000 for the same period last year. Operating loss was EUR 25,609,000 against EUR 29,672,000 reported last year. Acquisitions of property, plant and equipment was EUR 1,687,000 against EUR 811,000 reported last year.

Similar Private Companies By Industry

Company Name Region
ADx NeuroSciences NV Europe
Apitope International NV Europe
Beta-Cell NV Europe
Bienca S.A. Europe
Biopole S.A. Europe

Recent Private Companies Transactions

August 25, 2016
Biological Manufacturing Services SA

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Celyad SA, please visit www.celyad.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.